LLY

SELL

Eli Lilly and Company

Healthcare · Rank #114 · Analyzed Jul 13, 2026

$1188.58

Current Price

$510.27

Intrinsic Value

-57.1%

Upside/Downside

4/10

Score

4/5

Quality

Analysis Summary

Valuation Consensus0/2 methods agree

Quality Score4/5.0

Framework RatingSELL

Price vs Intrinsic ValueOvervalued by 57.1%

Fair Value Range

Low$170.20

Base (IV)$510.27

High$663.35

Entry Points

Conservative$119.14

Moderate$170.20

Aggressive$357.19

Quality & Moat Breakdown

Return on Equity107.5% → 1.0/1.0

Debt LevelD/E 139 → 0/1.0

Revenue QualityGrowth 31.3%, margin Δ+54.7% +recovery → 1.0/1.0

Moat Strength4.0/5 → 1.0/1.0

Profit Margins35.0% → 1.0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.